Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas

BACKGROUND: Effective medical therapies are lacking for the treatment of neurofibromatosis type 1– related plexiform neurofibromas, which are characterized by elevated RAS–mitogen-activated protein kinase (MAPK) signaling. METHODS: We conducted a phase 1 trial of selumetinib (AZD6244 or ARRY-142886)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:N Engl J Med
Main Authors: Dombi, Eva, Baldwin, Andrea, Marcus, Leigh J., Fisher, Michael J., Weiss, Brian, Kim, AeRang, Whitcomb, Patricia, Martin, Staci, Aschbacher-Smith, Lindsey E., Rizvi, Tilat A., Wu, Jianqiang, Ershler, Rachel, Wolters, Pamela, Therrien, Janet, Glod, John, Belasco, Jean B., Schorry, Elizabeth, Brofferio, Alessandra, Starosta, Amy J., Gillespie, Andrea, Doyle, Austin L., Ratner, Nancy, Widemann, Brigitte C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5508592/
https://ncbi.nlm.nih.gov/pubmed/28029918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1605943
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados